News stories about Spring Bank Pharmaceuticals (NASDAQ:SBPH) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spring Bank Pharmaceuticals earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.9875664858401 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Spring Bank Pharmaceuticals stock opened at $15.28 on Thursday. The company has a market capitalization of $197.96, a price-to-earnings ratio of -5.92 and a beta of 0.40. Spring Bank Pharmaceuticals has a 12 month low of $7.95 and a 12 month high of $18.93.
A number of equities research analysts recently issued reports on SBPH shares. ValuEngine downgraded Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $32.00 price objective (up previously from $29.00) on shares of Spring Bank Pharmaceuticals in a research report on Wednesday, February 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. Spring Bank Pharmaceuticals has a consensus rating of “Buy” and an average price target of $28.00.
TRADEMARK VIOLATION NOTICE: This piece was first posted by BBNS and is owned by of BBNS. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://baseballnewssource.com/2018/03/22/spring-bank-pharmaceuticals-sbph-receives-daily-coverage-optimism-score-of-0-21/1925701.html.
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.